![Anthony Gibney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anthony Gibney
Finanzdirektor/CFO bei
AURA BIOSCIENCES, INC.
Vermögen: 449 290 $ am 31.05.2026
Profil
Anthony S.
Gibney is currently an Independent Non-Executive Director at InflaRx NV since 2021, a Director at LAPIX Therapeutics, Inc. starting in 2024, and Chief Financial & Business Officer at Aura Biosciences, Inc. beginning in 2025.
Former roles include Chairman at Clearside Biomedical, Inc. from 2024 to 2025, Director at InflaRx GmbH, Managing Director-Global Healthcare Group at Merrill Lynch & Co., Inc. from 1999 to 2009, Independent Non-Executive Director at InflaRx NV from 2018 to 2019, Associate-Healthcare Investment Banking Group at Lehman Brothers, Inc. from 1993 to 1999, Chief Business Officer & Executive Vice President at Achillion Pharmaceuticals, Inc. from 2018 to 2020, MD & Co-Head-Biotechnology Investment Team at Leerink Partners LLC from 2009 to 2017, Executive VP, Chief Business & Strategy Officer at IVERIC bio, Inc. from 2021 to 2023, and Chief Financial & Business Officer at Parabilis Medicines, Inc. from 2020 to 2021.
Education includes an undergraduate degree from Yale University conferred in 1993.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AURA BIOSCIENCES INC 0,09 % | 31.03.2026 | 56.933 ( 0,09 % ) | 425 290 $ | 31.05.2026 |
INFLARX N.V. 0,01 % | 18.03.2026 | 10.000 ( 0,01 % ) | 24 000 $ | 31.05.2026 |
Aktive Positionen von Anthony Gibney
| Unternehmen | Position | Beginn |
|---|---|---|
| INFLARX N.V. | Direktor/Vorstandsmitglied | 19.05.2021 |
| AURA BIOSCIENCES, INC. | Finanzdirektor/CFO | 13.05.2025 |
Lapix Therapeutics, Inc.
 Lapix Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for autoimmune diseases and oncology | Direktor/Vorstandsmitglied | 01.01.2024 |
Ehemalige bekannte Positionen von Anthony Gibney
| Unternehmen | Position | Ende |
|---|---|---|
| CLEARSIDE BIOMEDICAL, INC. | Vorsitzender | 11.08.2025 |
| IVERIC BIO, INC. | Corporate Officer/Principal | 01.07.2023 |
Parabilis Medicines
 Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Finanzdirektor/CFO | 01.12.2021 |
| ACHILLION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 28.01.2020 |
| INFLARX N.V. | Direktor/Vorstandsmitglied | 01.06.2019 |
Ausbildung von Anthony Gibney
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
100
+
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance Provides investment banking services | Finance |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology Operates as a biotech company which develops new therapeutics in the field of inflammation | Health Technology |
Clearside Biomedical, Inc.
 Clearside Biomedical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures suprachoroidal space injections for eye diseases | Health Technology |
Merrill Lynch & Co., Inc.
 Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Parabilis Medicines
Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
InflaRx NV
 InflaRx NV BiotechnologyHealth Technology Develops biopharmaceutical products | Health Technology |
Lapix Therapeutics, Inc.
Lapix Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for autoimmune diseases and oncology | Health Technology |
